CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Finance Lease, Principal Payments
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Finance Lease, Principal Payments of $3.59 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for the quarter ending 2021-12-25 was $1.38M, a 57.53% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for the quarter ending 2021-09-25 was $117.00K, a 88.38% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for the quarter ending 2021-06-26 was $763.00K, a 14.75% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for the quarter ending 2021-03-27 was $942.00K, a 40.08% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for fiscal 2025 was $3.59M, a 23.11% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for fiscal 2024 was $2.92M, a 26.99% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for fiscal 2023 was $2.30M, a 1.77% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. finance lease, principal payments for fiscal 2022 was $2.26M, a 29.51% decline from fiscal 2021.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 3 month as first filed | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 6 month as first filed | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|---|---|
| 2025-12-27 | $3.59M 10-K · filed 2026-02-18 | |||||
| 2024-12-28 | $2.92M 10-K · filed 2026-02-18 | |||||
| 2023-12-30 | $2.30M 10-K · filed 2026-02-18 | |||||
| 2022-12-31 | $2.26M 10-K · filed 2025-02-19 | |||||
| 2021-12-25 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $1.50M derived: sum of 2 quarters · filed 2024-02-14 | $2.26M derived: sum of 3 quarters · filed 2024-02-14 | $3.20M 10-K · filed 2024-02-14 | ||
| 2021-09-25 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $880.00K derived: sum of 2 quarters · filed 2021-11-03 | $1.82M 10-Q · filed 2021-11-03 | $2.70M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-26 | $763.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.71M 10-Q · filed 2021-08-04 | $2.58M derived: sum of 3 quarters · filed 2023-02-22 | $3.59M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-03-27 | $942.00K 10-Q · filed 2021-05-04 | $1.82M derived: sum of 2 quarters · filed 2023-02-22 | $2.83M derived: sum of 3 quarters · filed 2023-02-22 | $3.72M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2020-12-26 | $876.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.88M derived: sum of 2 quarters · filed 2023-02-22 | $2.78M derived: sum of 3 quarters · filed 2023-02-22 | $4.35M 10-K · filed 2023-02-22 | ||
| 2020-09-26 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.90M derived: sum of 2 quarters · filed 2021-11-03 | $3.47M 10-Q · filed 2021-11-03 | $4.38M derived: sum of 4 quarters · filed 2022-02-16 | ||
| 2020-06-27 | $895.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.47M 10-Q · filed 2021-08-04 | $3.37M derived: sum of 3 quarters · filed 2022-02-16 | $4.39M derived: sum of 4 quarters · filed 2022-02-16 | ||
| 2020-03-28 | $1.57M 10-Q · filed 2021-05-04 | $2.48M derived: sum of 2 quarters · filed 2022-02-16 | $3.50M derived: sum of 3 quarters · filed 2022-02-16 | $4.50M derived: sum of 4 quarters · filed 2022-02-16 | ||
| 2019-12-28 | $904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $1.92M derived: sum of 2 quarters · filed 2022-02-16 | $2.93M derived: sum of 3 quarters · filed 2022-02-16 | $3.77M 10-K · filed 2022-02-16 | ||
| 2019-09-28 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $2.02M derived: sum of 2 quarters · filed 2020-10-29 | $2.86M 10-Q · filed 2020-10-29 | |||
| 2019-06-29 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.84M 10-Q · filed 2020-08-05 | $1.84B 10-Q · filed 2019-07-31 | |||
| 2019-03-30 | $838.00K 10-Q · filed 2020-05-07 | $838.00M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |